Achievements and challenges in normal tissue response modelling for proton therapy

doi:10.1016/j.phro.2022.11.004

Editorial

. 2022 Nov 7:24:118-120.

doi: 10.1016/j.phro.2022.11.004. eCollection 2022 Oct.

Achievements and challenges in normal tissue response modelling for proton therapy

Grete May Engeseth¹, Camilla Stokkevåg^{1

2}, Ludvig P Muren^{3

4}

Affiliations

¹ Dept of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
² Dept of Physics and Technology, University of Bergen, Bergen, Norway.
³ Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
⁴ Dept of Clinical Medicine, Aarhus University, Aarhus, Denmark.

PMID: 36405562
PMCID: PMC9667307
DOI: 10.1016/j.phro.2022.11.004

Editorial

Achievements and challenges in normal tissue response modelling for proton therapy

Grete May Engeseth et al. Phys Imaging Radiat Oncol. 2022.

. 2022 Nov 7:24:118-120.

doi: 10.1016/j.phro.2022.11.004. eCollection 2022 Oct.

Authors

Grete May Engeseth¹, Camilla Stokkevåg^{1

2}, Ludvig P Muren^{3

4}

Affiliations

¹ Dept of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
² Dept of Physics and Technology, University of Bergen, Bergen, Norway.
³ Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
⁴ Dept of Clinical Medicine, Aarhus University, Aarhus, Denmark.

PMID: 36405562
PMCID: PMC9667307
DOI: 10.1016/j.phro.2022.11.004

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Comment on

Independent validation of a dysphagia dose response model for the selection of head and neck cancer patients to proton therapy.
Kalendralis P, Sloep M, Moni George N, Snel J, Veugen J, Hoebers F, Wesseling F, Unipan M, Veening M, Langendijk JA, Dekker A, van Soest J, Fijten R. Kalendralis P, et al. Phys Imaging Radiat Oncol. 2022 Sep 17;24:47-52. doi: 10.1016/j.phro.2022.09.005. eCollection 2022 Oct. Phys Imaging Radiat Oncol. 2022. PMID: 36158240 Free PMC article.

Cited by

Physics and Imaging in Radiation Oncology comes of age.
Muren LP. Muren LP. Phys Imaging Radiat Oncol. 2024 Feb 19;29:100559. doi: 10.1016/j.phro.2024.100559. eCollection 2024 Jan. Phys Imaging Radiat Oncol. 2024. PMID: 38434208 Free PMC article. No abstract available.
Linear energy transfer-inclusive models of brainstem necrosis following proton therapy of paediatric ependymoma.
Handeland AH, Indelicato DJ, Fredrik Fjæra L, Ytre-Hauge KS, Pettersen HES, Muren LP, Lassen-Ramshad Y, Stokkevåg CH. Handeland AH, et al. Phys Imaging Radiat Oncol. 2023 Jun 29;27:100466. doi: 10.1016/j.phro.2023.100466. eCollection 2023 Jul. Phys Imaging Radiat Oncol. 2023. PMID: 37457667 Free PMC article.

References

1. Arscott W.T., Thompson R.F., Yin L., Burgdorf B., Kirk M., Ben-Josef E. Stereotactic body proton therapy for liver tumors: Dosimetric advantages and their radiobiological and clinical implications. Phys Imaging Radiat Oncol. 2018;8:17–22. - PMC - PubMed
1. Yoshimura T., Nishioka K., Hashimoto T., Seki K., Kogame S., Tanaka S., et al. A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer. Phys Imaging Radiat Oncol. 2021;20:23–29. - PMC - PubMed
1. Oonsiri S., Kitpanit S., Kannarunimit D., Chakkabat C., Lertbutsayanukul C., Prayongrat A. Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer. Phys Imaging Radiat Oncol. 2022;22:51–56. - PMC - PubMed
1. Langendijk J.A., Lambin P., De Ruysscher D., Widder J., Bos M., Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267–273. - PubMed
1. Widder J., van der Schaaf A., Lambin P., Marijnen C.A., Pignol J.P., Rasch C.R., et al. The quest for evidence for proton therapy: model-based approach and precision medicine. Int J Radiat Oncol Biol Phys. 2016;95:30–36. - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Arscott W.T., Thompson R.F., Yin L., Burgdorf B., Kirk M., Ben-Josef E. Stereotactic body proton therapy for liver tumors: Dosimetric advantages and their radiobiological and clinical implications. Phys Imaging Radiat Oncol. 2018;8:17–22. - PMC - PubMed

[2] Arscott W.T., Thompson R.F., Yin L., Burgdorf B., Kirk M., Ben-Josef E. Stereotactic body proton therapy for liver tumors: Dosimetric advantages and their radiobiological and clinical implications. Phys Imaging Radiat Oncol. 2018;8:17–22. - PMC - PubMed

[3] Yoshimura T., Nishioka K., Hashimoto T., Seki K., Kogame S., Tanaka S., et al. A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer. Phys Imaging Radiat Oncol. 2021;20:23–29. - PMC - PubMed

[4] Yoshimura T., Nishioka K., Hashimoto T., Seki K., Kogame S., Tanaka S., et al. A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer. Phys Imaging Radiat Oncol. 2021;20:23–29. - PMC - PubMed

[5] Oonsiri S., Kitpanit S., Kannarunimit D., Chakkabat C., Lertbutsayanukul C., Prayongrat A. Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer. Phys Imaging Radiat Oncol. 2022;22:51–56. - PMC - PubMed

[6] Oonsiri S., Kitpanit S., Kannarunimit D., Chakkabat C., Lertbutsayanukul C., Prayongrat A. Comparison of intensity modulated proton therapy beam configurations for treating thoracic esophageal cancer. Phys Imaging Radiat Oncol. 2022;22:51–56. - PMC - PubMed

[7] Langendijk J.A., Lambin P., De Ruysscher D., Widder J., Bos M., Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267–273. - PubMed

[8] Langendijk J.A., Lambin P., De Ruysscher D., Widder J., Bos M., Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013;107:267–273. - PubMed

[9] Widder J., van der Schaaf A., Lambin P., Marijnen C.A., Pignol J.P., Rasch C.R., et al. The quest for evidence for proton therapy: model-based approach and precision medicine. Int J Radiat Oncol Biol Phys. 2016;95:30–36. - PubMed

[10] Widder J., van der Schaaf A., Lambin P., Marijnen C.A., Pignol J.P., Rasch C.R., et al. The quest for evidence for proton therapy: model-based approach and precision medicine. Int J Radiat Oncol Biol Phys. 2016;95:30–36. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Achievements and challenges in normal tissue response modelling for proton therapy

Affiliations

Achievements and challenges in normal tissue response modelling for proton therapy

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources